Current FDA-approved treatment for wet age-related macular degeneration consists of anti-VEGF agents such as ranibizumab (Lucentis, Genentech, San Francisco, CA, USA), aflibercept (Eylea, Regeneron, Tarrytown, NY, USA), brolucizumab (Beovu, Novartis, East Hanover, NJ, USA, currently withdrawn from the US market), Eylea-HD (Regeneron Pharmaceuticals, Inc.)and biosimilars. The gene discussed is VEGFA; the disease is wet macular degeneration.